Novonesis started 2026 with a 7% organic sales growth and a robust adjusted EBITDA margin of 37.8% in Q1, driven by growth across all sales areas and markets. The company confirmed its 2026 outlook with expected organic sales growth of 5-7% and an EBITDA margin between 37-38%. Key highlights include strong performance in Food & Health and Planetary Health Biosolutions, successful bond issuance, and acquisition of a production facility in Thailand to support expansion. Despite global uncertainties, Novonesis remains confident in achieving its long-term growth targets through continued demand for biosolutions.
Jurrien Timmer, Fidelity's global macro director, suggests Bitcoin may have reached a critical support level around $60,000, indicating it could be in an accumulation zone. This assessment is based on a power law model that historically marks buying ...
Mark Lanier won a landmark $6 million verdict against Meta and Google, proving their platforms were designed to be addictive and harmful to children's mental health. The case, led by a young plaintiff named Kaley, exposed internal documents showing d...
XRP Ledger's payment volume has dropped sharply from over 1.3 billion XRP to just 40.5 million XRP in recent days, signaling a near-zero level of network payments. This decline is largely driven by the absence of large transfers from institutional or...
The Bitcoin Mining AI Infrastructure Index reportedly fell 16% over the past month, coinciding with an SEC filing from bitcoin miner TeraWulf indicating insider share transactions. This decline reflects investor concerns about insider liquidity and p...
Michael Saylor described Bitcoin as a network balanced by wallets, nodes, and miners, each holding different influence through capital, commerce, and computing power. His comments come amid debate over BIP 110, a proposal to limit certain non-payment...
